Dr Kavita Tyagi Is A Well-Known Cardiologist In The Northern Region, Leading Woman Cardiology And Related Sciences In The Indian North Zone (Wincar). Dr. Kavita Tyagi Is Currently Working As Consultant, Interventional And Clinical Cardiologist Sir Ganga Ram Super Speciality Hospital. Dr Tyagi Has Extensively Worked On Treatment And Management Of Various Cardiac Disease Such As Heart Attack, Heart Failure And Other Acute And Chronic Heart Diseases. She Has Special Interest In Disseminating Social Awareness For Prevention And Early Screening Of Cardiac Disease In Rural Areas (Offline And Online). She Has So Far Conducted Numerous Cpr Sessions For Training General Public To Respond In Emergency Situations And More Than 30 Health Camps. She Has Attended Various National And International Conferences As Speaker And Case Presenter. She Has Been Co-Investigator In Several International Trials. She Has Been Felicitated By Various Social Groups And Agencies For Working During Covid Time. She Has Been Tremendously Working For The Patients And General Public And Imparting General Awareness For Cardiac Diseases.
• Tachycardiomyopathy By Mohan Rajat , Tyagi Kavita Chapter 149 , (2016) Edition : 1/E Cardiology Update, Https://Www.Jaypeedigital.Com/Book/9789352500390/Chapter/Ch149
• Chapter In Stemi , A Cardiology Update 2016 : Risk Factors For St Elevation Of Myocardial Infarction,. Kavita Tyagi , Aman Makhija , Sc Manchanda . Jaypee Brothers
• Rajat Mohan , Kavita Tyagi , Jps Sawhney , Sangeeta Sachdeva , Payal Nindra “Clinical Profile And Comparative Assessment Of Mitral Regurgitation With Two And Three Dimensional Echocardiography” , International Journal Of Science And Research (Ijsr),Volume 7 , Issue 6 , June 2018 , 873-876, Https://Www.Ijsr.Net/Getabstract.Php?Paperid=Art20183316
• Kavita Tyagi “Arrhythmias In Athletes: What Is New? Jmscr Vol 06 Issue 07 July 2018 , 62-67 Chrome-Extension://Efaidnbmnnnibpcajpcglclefindmkaj/Http://Jmscr.Igmpublication.Org/V6-I7/12%20jmscr.Pdf
• Kavita Tyagi, Rajat Mohan, Jps Sawhney, Sangeeta Sachdeva , Payal Nindra. Comparison Of The Two Dimensional Versus Three Dimensional Transthoracic Echocardiography In Assessment Of Mitral Regurgitation . International Journal Of Medical Science And Current Research (Ijmscr) Volume1, Issue 2, Page No: 114-121 July-August 2018 .Pub Med (Short Length Paper) Bibliography.
• J.P.S. Sawhney, K Tyagi, M.K. Sharma, K. Madan, J.K. Vanani, B Kandpal, A.Mehta. Lipoprotein (A) In Young Coronary Artery Disease And Its Association With Severity Of Coronary Artery Disease. Atherosclerosis 2021:331; E117 Https://Www.Sciencedirect.Com/Science/Article/Abs/Pii/S0021915021006183
• Prevalence Of Elevated Lipoprotein(A) In Patients With Heterozygous Familial Hypercholesterolemia, Dnb Program Thesis, Co-Guide
• High Intensity Statin With Or Without Ezetimibe To Achieve Low Density Lipid Cholesterol Goal In Patients With Acute Coronary Syndrome: A Randomized Controlled Study, Dnb Program Thesis, Co-Guide
• Clinical Profile, H2fpef Score And Brain Natriuretic Peptide Levels In Adults With Heart Failure With Preserved Ejection Fraction: An Observational Study, Dnb Program Thesis, Co-Guide
• Correlation Of Elevated Lipoprotein (A) Levels With Severity Of Coronary Artery Disease, Dnb Program Thesis, Co-Guide
• Lipid Lowering Effect Of High Intensity Statin In Stain Naïve Acute Coronary Syndrome Patients, Dnb Program Thesis, Co-Guide
• Select - Semaglutide Effects On Cardiovascular Outcomes In People With Overweight Or Obesity, Co-Investigator
• K-877-302 Study Protocol - Pemafibrate To Reduce Cardiovascular Outcomes By Reducing Triglycerides In Patients With Diabetes (Prominent), Co-Investigator
• Multi-Center Cross-Sectional Epidemiological Study To Characterize The Prevalence And Distribution Of Lipoprotein(A) Levels Among Patients With Established Cardiovascular Disease, Co-Investigator
• Familial Hypercholesterolemia Studies Collaboration [Easfhsc], Co-Investigator
• I8f-Mc-Gpgn (B) The Effect Of Tirzepatide Versus Dulaglutide On Major Adverse Cardiovascular Events In Patients With Type 2 Diabetes (Surpass-Cvot), Co-Investigator
• Remit Hf A Prospective Multicenter Randomized Open Label Active Controlled Study To Assess Effect Of Remogliflozin On Biomarkers Of Heart Failure Compared To Empagliflozin In Patients Of Type 2 Diabetes Mellitus With Chronic Heart Failure, Co-Investigator
• A Multinational, Randomized Open-Label, Parallel Group, Active-Controlled, Two-Arm, Long-Term Morbidity And Mortality Trial Involving Intensive Preventive Therapy (High Dose Renin-Angiotensin-Aldosterone System Inhibitors [Raasi], Beta-Blockade, Sodium-Glucose Co-Transporter 2 Inhibitors [Sglt2i]) Among Biomarker (N-Terminal Pro-B-Type Natriuretic Peptide, Nt-Probnp)-Identified High Risk Type 2 Dm Patients Without Pre-Existing Cardiovascular Disease", , Co-Investigator
• Ctqj230a12301 A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing The Impact Of Lipoprotein (A)Lowering With Tqj230 On Major Cardiovascular Events In Patients With Established Cardiovascular Disease, , Co-Investigator
• Empact-Mi: A Streamlined, Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Superiority Trial To Evaluate The Effect Of Empagliflozin On Hospitalization For Heart Failure And Mortality In Patients With Acute Myocardial Infarction, ,Co-Investigator
• Effect Of Semaglutide 2.4 Mg Once Weekly On Function And Symptoms In Subjects With Obesity Related Heart Failure With Preserved Ejection Fraction, And Type 2 Diabetes, , Co-Investigator
• Lib003-004, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of Lib003 In Heterozygous Familial Hypercholesterolemia Patients On Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (Liberate-Hefh), Co-Investigator
• Relationship And Differences Between Central Aortic And Peripheral Blood Pressure Measurement Performed With The Same Device, Co-Investigator
• Effects Of Semaglutide On Functional Capacity In Patients With Type 2 Diabetes And Peripheral Arterial Disease (Stride) , Co-Investigator
• Lib003-005; Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of Lib003 In Patients With Cardiovascular Disease On Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (Liberate-Cvd) , Co-Investigator
• A Randomized, Double - Blind, Placebo - Controlled, Multicenter Trial Assesssing The Impact Of Inclisiran On Major Cardiovascular Events In Participants With Established Cardiovascular Disease(Victorion-2 Prevent) , Co-Investigator
• A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating The Effect Of Inclisiran On Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) In Participants With A Diagnosis Of Non-Obstructive Coronary Artery Disease Without Previous Cardiovascular Events (Victorion-Plaque), Co-Investigator
• Lib 003-007 Open-Label Extension Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of Lib003 In Patients With Homozygous And Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, Or At High Risk For Cardiovascular Disease, On Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (Liberate-Ole), Co-Investigator
